What About Celebrex?
Rofecoxib (Vioxx - Merck) has been withdrawn from the market due to an increased risk of cardiovascular complications associated with its long-term use. The question remains whether all selective COX-2 inhibitors carry the same risk. Full-page advertisements in newspapers for celecoxib (Celebrex - Pfizer), the most widely used COX-2 inhibitor, assure the public that it does not....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: What About Celebrex?
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1194
Article Code: 1194b
Date: October 25, 2004
Volume: 46
Pages: 87-88
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1194
Article Code: 1194b
Date: October 25, 2004
Volume: 46
Pages: 87-88
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)